Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Alzheimer disease and aducanumab: adjusting our approach

In the march towards disease-modifying treatments for Alzheimer disease, immunotherapy with antibodies against amyloid-β protein is furthest along in human trials. The news that Biogen’s aducanumab showed no cognitive benefit in phase III trials requires careful analysis of what went wrong and how to position anti-amyloid agents among other therapeutic approaches.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Sevigny, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537, 50–56 (2016).

    CAS  Article  Google Scholar 

  2. 2.

    Selkoe, D. J. Preventing Alzheimer’s disease. Science 337, 1488–1492 (2012).

    CAS  Article  Google Scholar 

  3. 3.

    Castellano, J. M. et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl Med. 3, 89ra57 (2011).

    CAS  Article  Google Scholar 

  4. 4.

    Sperling, R. A. et al. The A4 study: stopping AD before symptoms begin? Sci. Transl Med. 6, 228fs13 (2014).

    Article  Google Scholar 

  5. 5.

    Butovsky, O. & Weiner, H. L. Microglial signatures and their role in health and disease. Nat. Rev. Neurosci. 19, 622–623 (2018).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Dennis J. Selkoe.

Ethics declarations

Competing interests

D.J.S. is a consultant for E-Scape Bio and Prothena.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Selkoe, D.J. Alzheimer disease and aducanumab: adjusting our approach. Nat Rev Neurol 15, 365–366 (2019).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing